Hepatectomy for liver metastases of colorectal cancer after adoptive chemoimmunotherapy using activated t-cells

Abstract

Background/Aim: Various types of chemo-immunotherapies for malignant tumors have been reported. However, there are few reports on hepatectomy after chemoimmunotherapy. We evaluated the safety and efficacy of hepatectomy for patients with stage IV colorectal liver metastases (CLM) after chemoimmunotherapy using activated T-cells. Patients and Methods: From June 2012 to December 2016, five patients who underwent hepatectomy after receiving capecitabine and oxaliplatin (XELOX) plus bevacizumab and ex vivo-expanded T-lymphocytes as firstline chemoimmunotherapy were included. Results: The median age of the five patients (two men, three women) was 61.4 (range=56-75) years. The surgical procedure was partial hepatectomy in two, laparoscopic partial hepatectomy in two, and one case of partial hepatectomy with subsegmentectomy. There was no postoperative complication of Clavien-Dindo grade 3A or higher. One patient had multiple lung metastases. Conclusion: Hepatectomy after chemoimmunotherapy using activated T-cells for CLM can be performed safely.